Sun Pharma Gets CDSCO Panel Nod For Alfuzosin-Tadalafil FDC Post-Marketing Study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-08-10 07:00 GMT | Update On 2025-08-10 07:00 GMT

New Delhi: Drugmaker Sun Pharmaceutical Laboratories Ltd has been granted conditional approval by the Subject Expert Committee (SEC), under the Central Drugs Standard Control Organisation (CDSCO), to conduct an Active Post Marketing Surveillance (PMS) study of its fixed-dose combination (FDC) drug: Alfuzosin Hydrochloride IP (ER) 10 mg + Tadalafil IP 5 mg uncoated bilayer tablet.

This approval came during the 6th SEC (Urology) meeting held on 22nd July 2025, where the firm presented its Active PMS protocol as required under Form CT-23 dated 25.04.2025.

Following detailed deliberation, the committee recommended the study with specific modifications, stating, "The ED score should be 22 instead of 25 in inclusion criteria. The inclusion criteria should include the patients having the Prostate volume of less than or equal to 60mL. The indication mentioned in the protocol should be in line with the permission granted in Form CT-23."

The SEC further directed that a revised Active PMS protocol incorporating these changes must be submitted to CDSCO for review. Upon approval, the firm must also submit the Active PMS report for further examination by the committee.

The fixed-dose combination combines Alfuzosin, an alpha-blocker that relaxes the muscles in the prostate and bladder, and Tadalafil, a phosphodiesterase-5 (PDE5) inhibitor believed to improve urinary symptoms in benign prostatic hyperplasia (BPH) patients.

Also Read: NPPA Caps Prices of Ipratropium, Sodium Nitroprusside, Two Other Essential Drugs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Sun Pharma Gets CDSCO Panel Nod For Alfuzosin-Tadalafil FDC Post-Marketing Study

Similar News

After DEG Contamination Scare, CDSCO Launches ONDLS Digital Monitoring System for High-Risk Solvents

Abbott Told to Provide Prescribing Details, Supporting Data for Triamcinolone Hexacetonide Pre-Filled Syringe

India to Regulate Cell and Gene Therapies Under Drug Licensing Rules

Modi Mundipharma Gets SEC Approval to Study Cingal, a Hyaluronic Acid-Steroid Device for Osteoarthritis Knee Pain

CDSCO Panel Rejects Troikaa Pharma's High-Strength Paracetamol Injection Citing Safety Concerns

CDSCO Flags Besto-Cof Cough Syrup as Spurious, Raipur Drug Lab Claims Batch Not Made by Listed Firm

Sun Pharma Gets CDSCO Panel Approval to Conduct Phase III Study of Oral Semaglutide

CDSCO Ends Emergency-Use Authorization of Baricitinib for COVID-19 Treatment